A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
IDEAYA Biosciences, Inc. IDYA
Promising (early) broader-coverage candidate · IDEAYA Biosciences, Inc.
On FrontierLab's discovery record since 2026-09-09 (3 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Promising (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-09-10), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | 3244.7% |
|---|---|
| Gross margin | -13.3% |
| Gross profits / assets | -0.02 |
| Rule of 40 | 3152 |
| Net margin | -92.7% |
| Cash runway (months) | 53.2 |
| PEG | — |
| Price / sales | 15.6 |
Quality checklist
- ~ Revenue growth — 3244.7% (pass ≥ 20%)
- ✓ Capital efficiency
- ✗ Gross margin — -13.3% (pass ≥ 60%)
- ✓ Gross-margin trend — 1983.4 (pass ≥ 2)
- ✓ Share dilution — 4.1%
Fundamentals — snapshot as of 2026-09-10
| Stage | Early |
|---|---|
| Share issuance (YoY) | 4.1% · modest issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | — |
| EPS (trailing) | $-1.94 |
| Burn multiple | 0.8 |
| Gross-margin trend (pts) | 1983.4 |
| Cash / assets | 0.63 |
| Net debt / EBITDA | — |
| Statements as of | Q2 FY2026 · filed 2026-08-04 |
Momentum context — a snapshot from 2026-09-10, not current
| Price at surface | $38.35 (as of 2026-09-10) |
|---|---|
| 52-week range | $24.238 – $42.68 |
| % off 52-wk high | -10.1% |
| RSI (14) | 48 |
| Relative volume | 0.7× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-09-10 (end-of-day). How grades are computed →